文献速递疼痛医学

2013至2023年美国门诊阿片类药物处方中纳洛酮共同调配的国家趋势

National trends in naloxone codispensing with outpatient opioid prescriptions, 2013-2023.
PubMed 文献 · Reg Anesth Pain Med · 2026-10-05

该研究利用IQVIA纵向处方数据库分析2013年1月1日至2023年9月30日美国12岁及以上人群的阿片类药物处方,定义纳洛酮共同调配为阿片类药物调配后3日内调配纳洛酮。结果显示,在1 690 391 169张阿片类药物处方中,仅3 531 421张(0.2%)进行了纳洛酮共同调配,比例从2013年的0.0%上升至2023年的0.9%,但在高风险处方、长期阿片治疗及既往丁丙诺啡调配者中仍不频繁。

要点

  • 2013-2023年纳洛酮共同调配率从0.0%升至0.9%,总体仍很低。
  • 高风险处方中共同调配率从0.0%升至1.3%,长期阿片治疗从0.0%升至0.7%。
  • 既往丁丙诺啡调配者中共同调配率从0.0%升至1.8%。

核心结论

  • 2013至2023年间,纳洛酮与阿片类药物处方的共同调配率有所增加,但即使在高危人群中仍不频繁。

研究设计与样本

  • 采用IQVIA纵向处方数据库进行系列横断面分析,覆盖美国92%的零售处方调配数据。
  • 研究对象为2013年1月1日至2023年9月30日期间调配阿片类药物处方的12岁及以上个体。
  • 纳洛酮共同调配定义为阿片类药物调配日期后3日内调配纳洛酮。

主要发现

  • 2013至2023年共调配1 690 391 169张阿片类药物处方,其中3 531 421张(0.2%)进行了纳洛酮共同调配。
  • 纳洛酮共同调配率从2013年的0.0%上升至2023年的0.9%。
  • 高风险处方中共同调配率从0.0%升至1.3%,长期阿片治疗从0.0%升至0.7%,既往丁丙诺啡调配者从0.0%升至1.8%。

关键数值与推荐

  • 纳洛酮共同调配定义为纳洛酮在阿片类药物调配日期后3日内调配。
  • 2016年美国疾病控制与预防中心推荐阿片类药物与纳洛酮共同处方。

临床怎么用

  • 临床医生应为阿片类药物处方患者,尤其是高风险患者,积极考虑共同调配纳洛酮。
  • 需通过临床医生教育、政策措施和社区 outreach 提高纳洛酮获取与使用。

局限性

  • 数据未涵盖通过既往处方或免费分发项目获得的纳洛酮。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Increasing access to naloxone, an opioid antagonist, can prevent opioid overdose among patients prescribed opioids. In 2016, the Centers for Disease Control and Prevention recommended coprescribing naloxone with opioids; however, the extent to which this guideline influenced clinical practice remains unclear. In this study, we seek to describe trends in the rate of naloxone codispensing with opioid prescriptions from 2013 to 2023. METHODS: This serial cross-sectional analysis used the IQVIA Longitudinal Prescription Database, which captures 92% of dispensed US retail prescriptions, to examine opioid prescriptions dispensed to individuals aged 12 years and older between January 1, 2013 and September 30, 2023. Naloxone codispensing was defined as naloxone dispensed within 3 days of the opioid dispensing date. Subgroup analyses included high-risk opioid prescriptions, long-term opioid therapy, and prior dispensing of buprenorphine for opioid use disorder. RESULTS: From 2013 to 2023, 1 690 391 169 opioid prescriptions were dispensed, with naloxone codispensing occurring in 3 531 421 (0.2%) cases, increasing from 0.0% in 2013 to 0.9% in 2023. Naloxone codispensing increased from 0.0% to 1.3% among high-risk prescriptions, from 0.0% to 0.7% for long-term opioid therapy, and from 0.0% to 1.8% for prior buprenorphine recipients during the study period. CONCLUSIONS: In this analysis of a national prescription dispensing database, naloxone codispensing with prescription opioids increased for 2013-2023 but remained infrequent, even among individuals at elevated risk for opioid overdose. Although these data do not capture naloxone obtained through prior prescriptions or free distribution programs, these findings emphasize the need for targeted interventions to promote naloxone codispensing. Clinician education, policy measures, and continued community outreach may help increase naloxone uptake and improve access for at-risk patients.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Beck EJ, Chua KP, Gunaseelan V, et al. National trends in naloxone codispensing with outpatient opioid prescriptions, 2013-2023. Reg Anesth Pain Med. 2026. PMID: 40829853. doi:10.1136/rapm-2025-106911

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。